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1. Introduction  
Unfractionated heparin is the most commonly used anticoagulant for hemodialysis (HD) 
(Sonawane et al., 2006). It is well-known that heparin can cause immune-mediated 
thrombocytopenia due to immunoglobulin antibody formation against the complex of 
platelet factor 4 (PF4) and heparin. Heparin may also contribute to HD-associated platelet 
activation, thrombocytopenia, and increased PF4 release from platelets during a heparin 
dialytic session (Matsuo et al., 1986). Typically, IgG isotype HIT antibodies develop after 5-
14 days of heparin exposure. The incidence of heparin-induced thrombocytopenia (HIT) was 
estimated at 3.9% in newly treated hemodialysis patients (Yamamoto et al., 1996). Also, 
dialysis is often complicated by clotting of the dialysis lines and/or dialyzer due to 
hypercoagulation regardless of the etiology. When a diagnosis of HIT based on clinical 
symptoms of thrombocytopenia and immunoassay for PF4/heparin complex antibodies is 
employed, it remains unclear whether a few patients have HIT. An antigen-based 
immunoassay to detect the presence of antibodies in a patient’s circulation that binds to the 
PF4/heparin complex is highly sensitive but less specific. Thus, the serological diagnosis of 
HIT needs to be confirmed by employing a functional assay such as 14C-serotonin release 
assay and heparin-induced platelet aggregation test. The enzyme-linked immunosorbent 
assay (ELISA) usually detects antibodies of three classes of isotype (IgG, IgA, and IgM) 
regardless of the capability of these antibodies to activate platelets. There is a way to 
improve the specificity based on only IgG class antibodies having the capability of inducing 
platelet activation by heparin (Chang et al., 2006; Syed & Reilly, 2009). 
There are two kinds of dialysis-related complication: unexpected clotting in the circuit and 
abrupt fistula thrombosis. The former seems to be more frequent in HIT patients than that in 
non-HIT patients. Visible clotting in the extracorporeal circulation can provide a clue to 
suspect HIT. AVF thrombosis is also observed in both HIT and non-HIT patients. After 
starting heparin, the sudden onset of fistula closure is rare as HIT-complicated thrombosis 
(O’Shea et al., 2002; Nakamoto et al., 2005).  
HD patients who develop HIT require not only the discontinuation of heparin, but 
essentially also the introduction of alternative anticoagulant therapy. An alternative 
anticoagulant, such as citric acid, and some therapeutic methods, such as heparin-free 
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dialysis and peritoneal dialysis, have been employed for patients who require dialysis. 
However, these therapeutic modalities are unlikely to be beneficial because of the absence of 
evidence for long-term management. 
Regarding clinical evidence to support HIT, a non-heparin anticoagulant should be started 
with an alternative to heparin. Argatroban rather than lepirudin is recommended as 
elimination is not via the kidneys, but mainly via the billiary system. As the elimination of 
lepirudin mainly depends on the renal function, it is not easy to monitor the optimal dose of 
lepirudin in each session. However, the dose of argatroban in hepato-renal failure is 
recognized variably to reduce while avoiding major bleeding in a critical setting (Hurting & 
Murray et al., 2007). Nafamostat mesilate, a polyvalent protease inhibitor, is sometimes used 
as an alternative to heparin in Japan. Although a few patients showed the effective 
resolution of clotting and a gradual increase of the platelet count to the baseline level in a 
subsequent session receiving nafamostat mesilate, no clinical trial has ever been carried out 
to evaluate the efficacy in the management of HIT (Matsuo & Wanaka, 2008b). Although 
hemodialysis-related HIT appears in an early session after starting HD with heparin, some 
patients with the anti-PF4/heparin complex antibodies have a risk of delayed-onset HIT, 
and they may suffer from HIT after cardiovascular intervention.  
2. Frequency of HIT in dialysis patients 
The frequency of HIT is suggested to be from 1 to 5% of patients exposed to unfractionated 
heparin, and significantly lower in patients exposed to low-molecular-weight heparin. As 
one of the reasons for the various frequencies of HIT, assays used to detect HIT antibodies 
vary in their specificity and sensitivity. An assay for HIT antibody usually detects both non-
pathogenic and pathogenic antibodies irrespective of the presence of thrombocytopenia. The 
clinical significance without thrombocytopenia in which a patient exhibits a stable titer of 
long-term HIT antibodies remains unclear, but there is an ongoing survey on whether or not 
subjects have a risk of thrombosis (Asmis et al., 2008).          
Few reports on the frequency of HIT in dialysis patients are known, although heparin is 
employed as the most useful anticoagulant during dialysis. It was believed that the 
frequency of HIT would be low in a survey targeting to all dialytic patients including both 
acute and chronic stages (Hutchison et al., 2005). Two surveys involving different subjects 
show quite different figures on the frequency of HIT. A relatively high frequency of 3.2% 
was reported for newly treated subjects receiving dialysis in three months (Yamamoto et al., 
1996), and a low rate frequency of 0.6% is described in chronic dialysis patients treated for 
over 3 months (Matsuo et al., 2006). Thus, the frequency of HIT in a dialysis population is 
different between newly treated and chronic maintained dialytic groups. HIT in the former 
shows a similar incidence to the heparin-sensitive group, and HIT in the later group is rarely 
identified as HIT or recurrence of HIT when a patient experiences changes in the 
immunological tolerance brought about by cardiovascular surgery, orthopedic surgery, and 
high-dose administration of erythropoietin with an adverse platelet-stimulating reaction. 
3. Clinical manifestations and laboratory testing in HD-HIT patients 
Major clinical manifestations are primary thrombocytopenia and new thrombosis. The onset 
of thrombocytopenia and/or thrombosis which sometimes complicates before 
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thrombocytopenia usually occurs 5-10 days after starting heparin anticoagulation. Although 
thrombocytopenia is ordinarily defined as a >50% fall in the platelet count and below 
100×109 /L, the definition of HD-HIT is less strict, in the range of a >30% fall in the platelet 
count and below 150×109 /L due to the intermittent use of heparin.  Timing of the fall of 
platelet counts also is likely to delay due to the intermittent heparin use. Thus, no dialytic 
session day may give a chance of recovering the platelet count, and the timing is usually 
delayed over 10 days. However, heparin flushing to maintain the patency of the inserted 
catheter in non-session days sometimes leads to the conventional formation of HIT 
antibodies (Table 1).  
 
Step Clinical and Lab. assessment Action plan 
1 suspicion of HIT  thrombocytopenia (<150×109 /L, unexplained 
decrease of > 30%), timing of over 5 days, no 
other cause of thrombocytopenia or 
thrombosis 
2 ELISA (IgG, A, M) no likelihood of HIT due to a negative 
qualitative assay    
3 specific IgG-ELISA high specificity for platelet-activating 
antibodies   
4 14C serotonin release assay 
(platelet aggregation test) 
confirmation of HIT as a gold standard test 
(not preferable due to being less sensitive) 
5 reassessment of HIT if 
necessary  
recheck other causes of thrombocytopenia and 
thrombosis, assess with alternative therapy   
Table 1. Diagnostic approach to HIT 
HIT symptoms may occur more rapidly within 24 hr or less in patients who have had a 
previous exposure to heparin within the prior 3 months. However, a dialytic patient can 
experience the onset of acute systemic reaction associated with circuit clotting and a marked 
drop in the platelet count immediately after a bolus heparin injection at start of the session. 
In chronic intermittent dialysis, HIT is unlikely to occur after several weeks of heparin 
exposure.  
HIT testing is grouped into two types: 1) detection of immunoglobulin antibody against 
heparin/PF4 complexes by ELISA as a standard technique, and ELISA is simple to perform, 
can be done in a few hours, is highly sensitive and less specific for antibody detection. 
Owing in part to its high sensitivity, ELISA often detects antibodies that would not be 
positive in 14C serotonin release and may be clinically insignificant. ELISA provides much 
information about the likelihood that a patient has HIT (Shaheed et al., 2007; Aster RH. 
2010), and 2) functional assays for the detection of platelet-activating immunoglobulin G by 
14C serotonin release. ELISA permits the identification of three subclasses of 
immunoglobulin: IgG, IgA, and IgM, reacting with PF4/heparin complexes in a solid-phase 
plate. To avoid the overdiagnosis of HIT, the pathogenic impact of HIT antibodies should be 
considered if the optical density is ≥ 0.4 (Warkentin et al., 2008). Therefore, a negative result 
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excludes the diagnosis of HIT. ELISA detects together with IgA and IgM antibodies that do 
not react on FcγIIA-mediated platelet activation. Specific IgG-HIT antibodies can contribute 
to the interaction of the HIT antibody/PF4/heparin complexes with the FcγIIA receptor, 
and subsequently induce platelet activation and the release of microparticles. A high-titer of 
IgG antibodies is accountable for HIT as well (EI-Shahawy et al., 2007; Carrier et al., 2008).  
The 14C serotonin release assay is the gold standard because of its high sensitivity and 
specificity. Thus, the 14C serotonin release assay should be performed to confirm the 
diagnosis if a weak positive result is obtained using ELISA (Sheriden et al., 1986; Pouplard 
et al., 1999). For the assessment of HD-HIT, the pretest probability of the diagnosis of HIT 
(4T’s test) has not been elucidated whether clot formation in the extracorporeal circulation is 
the first sign of HIT (Weiss et al., 2007). Sudden unexpected clotting in the circuit often 
provides an important clue for HIT diagnosis despite of there being many causes of clotting 
during dialysis. After changing the clotted dialyzer and circuit to new ones, dialysis must be 
restarted with an alternative to heparin, and the planned treatment modality can be 
uneventfully completed. Subsequent sessions will never affect re-clotting and the recurrence 
of thrombocytopenia under adequate switching to non-heparin anticoagulation. 
Furthermore, the patient is more likely to have HIT in the presence of a comparable HIT-
antibody seroconversion. Clotting of the extracorporeal circuit seems to be a manifestation 
of HIT in the context of primary thrombocytopenia, the visible resolution of clotting with an 
alternative anticoagulant, HIT antibody formation, and timing within 3 months of starting 
HD. 
 
Step 1. Recognition of HIT is most important:     
1. Unexpected clotting of dialyzer/circuit, and thrombotic occlusion of arteriovenous 
fistula/grafting despite optimal dose of heparin infusion   
2. Absence of other cause of clotting:  
slow blood flows, high hematocrit, high ultrafiltration rate, intradialytic blood and   
blood product transfusion, intradialytic lipid transfusion 
3. Check thrombocytopenia  
 
Step 2. Emergent protocol for suspected HIT patient:  
1. Stop dialysis immediately, and replace whole extracorporeal circuit with a new one 
2. Restart dialysis with argatroban (lepirudin)  
3. Confirm by visible inspection that there is no clot in the circuit once starting an 
alternative to heparin     
4. Avoid heparin flush on non-session days 
 
Table 2. Management strategy for HIT in dialytic patients 
The clinical features of HIT in dialysis patients includes acute thrombocytopenia that is 
associated with renal insufficiency except HIT (Oliveria et al., 2008), and repeated clotting of 
extracorporeal circulation undergoing heparin administration (Lasocki et al., 2008), and the 
clear disappearance of clots on using an alternative anticoagulant to heparin, and/or, rarely, 
thrombotic occlusion in AV fistula/grafting (O’Shea et al., 2002, Nakamoto et al., 2005). 
Circuit clotting occasionally occurs in a routine dialysis procedure, caused by non-HIT 
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factors. The causes of clotting are slow blood flow, high hematocrit, high ultrafiltration rate, 
intradialytic blood and blood product transfusion, intradialytic lipid transfusion. In clinical 
settings, it is difficult to decide whether the clotted circuit is derived from HIT or not.  No 
differences in the platelet count’s fall and timing between clotting-circuit and non-clotting 
circuit groups have been found in clinical settings. However, a higher level of optical 
density in ELISA is noted in the clotting patient group.  This suggests that HIT antibody 
formation may be active in the clotting rather than non-clotting patent group (Table 2). 
 
 
Fig. 1. Algorithm for the diagnosis of HIT in hemodialysis by adding the results of ELISA  
4. Diagnostic approach to HD-HIT patients  
An HD patient associated with HIT is recognized by stepwise assessment. The first step is 
the evaluation of the platelet count with the definition (<150×109 /L and > 30%). If the 
patient shows circuit clotting with no other causes, the next step would be to evaluate the 
timing of thrombocytopenia over days 7-30. The timing of HD-HIT is generally applied over 
a wider range than usual due to the duration of heparin use always being limited in dialysis 
of 4-6 hours per day. Positive ELISA added to platelet reduction, the presence of a clotting 
circuit, and reasonable timing, should be considered as revealing HIT. Thirty six (92.3%) of 
39 patients with four-factor combinations of thrombocytopenia, clotted circuit, optimal 
timing of platelet count fall, and positive ELISA had a positive 14C serotonin release assay 
(Matsuo et al., accepted in Clin Appl Throm/Hemost). According to the algorithm under 
the condition of no circuit clotting, five (71.4%) of 7 patients with thrombocytopenia, 
reasonable timing, and positive ELISA also had a positive 14C serotonin release assay. In the 
< >
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algorithm (Fig. 1), four groups can be identified: HD-HIT is most likely due to a highest 
positive rate of 14C serotonin release among the four groups, ‘HD-HIT most likely’; 
secondly, HD-HIT is likely to show a relatively high rate on a functional assay, ‘HD-HIT 
likely’. Timing outside the range and a negative ELISA despite the presence of a clotting 
circuit should be identified as ‘unlikely’. ‘HD-HIT less likely’ without any clotting is rare 
even though ELISA is positive. 
The sudden occurrence of clots in the dialyzer and/or circuit with an unexpected fall in the 
platelet count between 7 and 30 days are dramatic symptoms of HIT in HD patients 
undergoing appropriate anticoagulation with heparin. In an HD patient with suspected 
HIT, the clinical implication of clotting in the circuit as HIT can easily be supported in 
combination with thrombocytopenia, timing of the platelet fall, and result of ELISA. 
5. Management of HD-HIT patients 
Visible clotting in the circuit, including blood chambers, tubes, and dialyzer, are easily 
recognized by medical staff in the session, so HIT management can be initiated immediately 
when the clotting is likely to arise from HD-HIT. Once the HIT diagnosis has been 
established from high clinical suspicion alone before laboratory confirmation, it is essential 
that all sources of heparin, including low-molecular-weight-heparin, heparin flushing, and 
heparin-coated catheters or devices, must be discontinued. The early recognition of HIT in 
the presence of clot formation in the extracorporeal circuit is critical, and any additional 
infusion of heparin on the misunderstanding of heparin shortage must be contraindicated to 
resolve the clot. When the dialytic procedure cannot be continued with circuit clotting, a 
new dialyzer and devices of the extracorporeal circuit must be set up, and the session must 
be immediately restarted with an alternative anticoagulant. Then, the diagnosis of HIT can 
be verified using the algorithmic assessment in Fig. 1 and Table 2.  
Established alternative anticoagulation in HD patients with HIT is conducted with 
danaparoid, lepirudin, and argatroban. Danaparoid is a low- molecular-weight heparinoid. 
Although danaparoid is the most widely used for HD-HIT patients, it does not exhibit 
proper anticoagulation for HD-HIT due to clinically relevant cross-reactivity. Lepirudin is a 
recombinant hirudin preparation. Adequate dose adjustment is very difficult in for HD-HIT 
patients, in which it is cleared mainly by the kidneys and its half-life is markedly long in 
uremic patients.  
Argatroban (formerly called MD805), a synthetic direct thrombin inhibitor, is non-
immunogenic and does not show cross-reactivity with HIT antibodies. In contrast to 
lepirudin, argatroban is primarily hepatically metabolized, and its half-life is moderately 
extended in HD patients (Matsuo et al., 1988; Matsuo et al., 1990). Argatroban as an 
alternative anticoagulant is predominantly used for the prevention of extracorporeal circuit 
clotting in HD-HIT patients at the initial dose of 250μg/kg at the start of dialysis, and 
followed by a continuous infusion of at 2μg/kg/min while the hepatic function is normal. 
Dose adjustment is conducted for an empirical target of a 1.5-3.0-fold prolongation of the 
activated partial thromboplastin time (APTT) test, as an equivalent to the prolongation of 
heparin therapy. This dose can be reduced to <2μg/kg/min with a 1.5-2.5-fold prolongation 
of the APTT after the acute phase of HIT has subsided. The dose should also be reduced to 
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<2μg/kg/min depending on the severity hepatic dysfunction to avoid unexpected 
hemorrhagic complications. Only the replacement of heparin with argatroban in dialysis can 
lead to recovery from symptoms of HIT (Gozdzikiewicz et al., 2007; Roncon-Albuquerque et 
al., 2010; Matsuo & Wanaka, 2008a). Despite there being no apparent evidence for the 
systemic administration of argatroban on non-session days, argatroban anticoagulation may 
be useful to prevent the risk of new and worsening thrombotic events. When an HD-HIT 
patient is in a hypercoagulable state, such as with an elevated level of plasma D-dimer, 
argatroban therapy seems to be essential. The empirical dose of the drug is estimated to 
0.7μg/kg/min in patients with a normal liver function and 0.2μg/kg/min in those with 
hepatic dysfunction or a risk of bleeding. Future studies should be done on how to apply the 
drug on non-session days (Hursting & Murray et al., 2008).  
Nafamostat mesilate, a polyvalent synthetic protease inhibitor, is employed as a regional 
anticoagulant in dialysis patients with bleeding risks as an alternative to heparin in Japan. 
The drug has no influence on the systemic blood coagulation cascade due to its very short 
half-life, within 10 min, about 40% of the drug is removed from the dialyzer, and there is no 
cross-reactivity with HIT antibodies. Despite the fact that the HD-HIT session is 
uneventfully completed using nafamostat mesilate, it remains why the drug has a 
therapeutic benefit on the resolution of HIT over the effect of heparin cessation (Matsuo et 
al., 2001; Matsuo & Wanaka, 2008b) 
 
 Age/sex Type of 
surgery 
Thrombocytopenia
(50%fall, 5-10 days 
from pre-op. level)
Immunoassay 
(pos  >0.4 OD) 
Functional 
(pos >20%) 
assay 
Pre 7days 14days Pre 7days 14days 
1 58/M aortic 
aneurysm 
grafting 
—* —** 1.82 2.39 —*** — 96 
2 67/M aortic 
aneurysm 
grafting 
+ (56.6%) — — — — — — 
3 63/M CABG — — — — — — — 
4 69/M CABG + (69.6%) — — — — — — 
5 55/M CABG — — — — — — — 
6 60/F CABG + (73.5%) — — — — — — 
7 63/M valve op. — — — — — — — 
8 70/M CABG — 1.28 1.87 2.01 − 65 68 
* not consistent with platelet criteria  
**optical density < 0.4 by ELISA 
***radioactive serotonin release under 20% 
Table 3. Seroconversion in cardiac surgery patients with chronic hemodialysis 
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6. Cardiovascular surgery with chronic hemodialysis 
Chronic dialysis patients who repeatedly exposed to heparin rarely are at risk of developing 
HIT, show high-level mortality due to atherosclerotic cardiovascular events (Mureebe et al., 
2004). Sometimes they have indications for cardiovascular surgery on non-dialysis sessions. 
There are few data available on whether long-term heparin usage affects post-operative 
seroconversion, and the development of HIT. Surgical procedures usually stimulate the 
release of PF4 from platelets and the endothelium. PF4 does certainly facilitate complex 
formation in the presence of a dynamic equilibrium with external heparin. Macromolecular 
PF4/heparin complexes stimulate the immunomediated production of anti-PF4/heparin 
complex antibodies. Increased levels of immunomediated HIT-antibody production are 
occasionally recognized in the post-operative period. Although a high rate of seroconversion 
appears to be involved in the development of HIT, most seroconversion shows a lack of 
thrombocytopenia, and very few patients with seroconversion develop HIT.  
In cardiovascular patients receiving regular dialysis, the risk of HIT is presumed to increase 
in certain situations, such as cardiac interventions, by the modification of immunological 
tolerance to PF4/heparin complexes. Eight of 79 patients with cardiovascular surgery were 
treated with dialysis (Table 2). Two patients with neither thrombocytopenia nor thrombosis 
experienced seroconversion with the development of positive ELISA and SRA. One patient 
was negative in the pre-operative state despite heparin dialysis for 3.5 years.  He may have 
undergone a resetting of the immunologic response to PF4/heparin complexes due to the 
influence of perioperative surgical procedures (case #1 in Table 3). The other patient had 
pre-existing HIT antibodies on ELISA, and the positive SRA would be induced by 
accelerating the production of HIT antibodies due to cardiac intervention (case #8 in Table 
3). Although no ‘true HIT’ patient could be found in the series, this suggests that 
reactivation of the immune system could be functioning in the perioperative period, and the 
risk of developing HIT may be continuing until subsidence of HIT antibody production. 
Any thrombocytopenia corresponding to HIT criteria could not be detected with the 
monitoring of platelet counts in post-operation, despite a marked fall within 4 postoperative 
days, and steeply increasing platelet counts in the following days were observed regardless 
of whether or not the patients experienced seroconversion.  
Post-operative thrombocytosis, in contrast to HIT-related thrombocytopenia, can influence 
the results of platelet counts, because marked thrombocytosis must compensate for 
thrombocytopenia derived from immune-mediate platelet consumption. When the recovery 
of platelet counts remains low over the 5th post-operative day and an abrupt platelet fall is 
induced by the reuse of heparin, HIT should be considered in patients with no other cause 
of thrombocytopenia.  
HD patients with both positive ELISA and serotonin release assay and without defined 
thrombocytopenia may have a risk of developing HIT through re-exposure to heparin in a 
restarted dialysis session. A clotting circuit recognized as atypical HIT-related thrombosis is 
causally linked to the onset of thrombocytopenia, and the event will be certainly resolved by 
employing an alternative to heparin. HIT may occur even after years of uneventful chronic 
intermittent hemodialysis due to resetting of the immune mechanism triggered in cardiac 
surgery, catheter intervention, and, rarely, a platelet-activating procedures and agents. 
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 Symptoms of acute 
systemic reaction 
Circuit 
clotting 
AVF 
thrombus 
Platelet 
count 
(×109/L) 
at ASR 
Maximum 
fall (%) in 
platelet 
count 
Timing of 
platelet 
fall ( days) 
1 Dyspnea, chills, fever +** - 53 85 14 
2 Nausea, vomiting - + 25 88 12 
3* Dyspnea, flushing, chills, 
fever, 
- - 16 90 13 
4 Dyspnea, chest pain + - 28 94 7 
5 Dyspnea, chest pain, 
hypotension, nausea, 
vomiting 
- + 84 72 13 
6* Dyspnea, fever + - 57 67 8 
7*** Dyspnea, chills, nausea + - 92 80 11 
8 Dyspnea, chills, fever, 
chest pain, nausea 
+ - 74 73 11 
*diagnosed with pseudo-pulmonary embolism, ** unexpected closure of hollow fibers of dialyzer with 
fibrin-platelet aggregates in two consecutive sessions, ***heparin flushing on non-session day.  
Table 4. Eight patients with HIT-induced acute systemic reaction from twenty-seven dialytic 
patients who experienced some acute systemic reactions 
7. Characteristics of acute systemic reaction in dialytic patients 
Infrequently, an acute systemic reaction (ASR) as a manifestation of HIT occurs 5-30 min 
after heparin bolus administration at the start of dialysis. The symptoms are fever, chills, 
and flushing as acute inflammatory reactions, and hypertension, tachycardia, dyspnea, chest 
pain, and cardiopulmonary arrest. Although hypertension is usually associated with ASR 
(Warkentin et al., 2009), in contrast, acute hypotension often occurs as a sign of 
cardiovascular collapse during dialysis. When dyspnea as the cardiorespiratory reaction in 
ASR is prominent, it is considered to be a pseudo-pulmonary embolism (Tejedor Alonso et 
al., 2005; Hartman et al., 2006; Matsuo et al., 2007). However, the signs and symptoms are 
very similar to those in dialyzer reactions, dialytic complications as disequilibrium 
syndrome, and circuit clotting during the HD procedure. Except for platelet reduction by 
heparin, it is difficult to determine whether symptoms of ASR are most likely to be due to 
HIT in clinical settings. There are two causes of hypotension: HIT-induced hypotension may 
associate with cardiorespiratory collapse due to pseudo-pulmonary embolism, and HD-
induced hypotension often with nausea and vomiting, and occasionally with back pain and 
syncope.  
As the clinical features of eight patients defined with HIT-induced ASR from twenty-seven 
patients who experienced some ASR, seven of the eight patients suffered from dyspnea, and 
two ASR patients (case #3, #6 in Table 4) showing hypoxia, no radiological evidence, and 
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the quick recovery of symptoms after the cessation of heparin were defined as pseudo-
pulmonary embolism. Hypotension was implicated when pulmonary collapse was noted in 
a patient (case #5 in Table 4). Thus, hypotension was not a primary feature of the HIT-
induced acute systemic reaction. However, no hypertension appeared in eight HIT-induced 
ASR patients. Either complications of circuit clotting or AVF thrombus formation appeared 
in seven patients excluding a case (case #3 in Table 4) of pseudo-pulmonary embolism. The 
platelet fall rate and timing in HIT-induced ASR cannot be differentiated from those of HD-
induced ASR (Table 4). Complications during dialysis including dialyzer reactions, clotting 
circuit, anticoagulation failure, and hypotension may mimic the signs and symptoms of 
HIT-induced ASR except hypotension. Thus, a platelet count and assays for HIT antibodies 
should be considered for diagnosing acute HIT when HD patients show an abrupt fall in 
platelet counts and clinical symptoms of ASR with an unknown cause during dialysis. The 
results of the HIT-antibody assay showed that the differential diagnosis would be 
straightforward regarding whether HD patients with thrombocytopenia suffered from HIT-
induced or HD-complicated ASR. 
  
Fig. 2. Reduction in optical density of ELISA after heparin cessation in HD-HIT 
8. Reexposure to heparin 
The principal of heparin reexposure is based on a characteristic immune response in T-cell 
independent B-cell activation because of lack of a strong memory response, perhaps 
explaining transience and lack of anamnesis of the anti PF4/heparin immune response 
(Selleng et al., 2010). The reexposure can be carried out with lack of immune memory for the 
PF4/heparin complex antigen in patients with previous episodes of HIT when their HIT 
antibodies become negative. Currently, there is no clinical consensus regarding reexposure 
to heparin for HIT. However, it reexposure is needed at least 100 days after no detection of 
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HIT antibodies by ELISA. Reductions in the optical density of ELISA are quite variable after 
the cessation of heparin (Fig. 2).  While a positive ELISA continues long-term over years 
marked as positive ELISA is also recognizable in Fig.2, a short span type is also contained. 
Since the various half-life of HIT antibodies may reflect the existence of different properties 
of HIT antibodies, each patient should be followed by ELISA until there is no longer a 
detection of HIT antibodies. Reexposure to heparin should be introduced under negative 
ELISA where adequate emergent measures are adopted including platelet counting tests 
(Matsuo et al., 2003; Davenport et al., 2009; Wanaka et al., 2010). A majority of heparin-
reexposure patients show no recurrence of HIT unless they undergo cardiovascular surgery, 
catheter intervention, and, rarely, receive platelet-stimulating drugs. Reexposure to heparin 
in HD patients carrying a stable titer with an optical density over 0.4 may not be allowed 
because the risk of recurrence of HIT is likely to increase on heparin reuse.  
9. Conclusion    
HD-HIT is a drug-induced, immunoglobulin-mediated disorder that it is suspected in 
dialytic patients with an unexpected fall in the platelet count, and/or unexplained 
thrombotic events, particularly visible clotting in the circuit under an adequate heparin 
dose, and that begins between 5 and 10 days (nadir between 7 and 30 days, mostly by the 
third to fifth session) after heparin initiation. Although a positive result of HIT antibodies is 
presumably detected by sensitive ELISA, the diagnosis should be confirmed, whenever 
possible, using a functional assay. Immediately after the clinical suspicion of HIT, all sources 
of heparin should be discontinued including heparin used to flush or lock catheters. 
Alternative non-heparin anticoagulants, preferentially in a direct thrombin inhibitor, should 
be restarted for dialysis. Early treatment is important as thrombus formation including a 
clotting circuit may complicate at a high rate in 30 days after the cessation of heparin. 
Argatroban as an alternative to heparin must contribute to the quick recovery of the platelet 
count and immediate disappearance of circuit clotting. A steady decrease of the ELISA titers 
can be expected after heparin discontinuation. A negative seroconversion of HIT antibodies 
is usually observed by ~30 to more than 100 days after the discontinuation. Reexposure to 
heparin can be selected at the same dose of heparin as used before the onset of HIT. Small 
peak of HIT antibodies may often appear after exposure, but a follow-up of the antibody 
titers does not reach a threshold to induce the recurrence of HIT. When HD-HIT patients 
exhibit a high risk of thrombotic formation or worsening thrombosis, the same alternative 
anticoagulant therapy may be needed in non-session days. 
10. References 
Asmis LM, Segal JB, Plantnga LC, Fink NE, Kerman JS, Kickler TS, Coresh J, Gardner LB. 
(2008) Heparin-induced antibodies and cardiovascular risk in patients on dialysis. 
Thromb Haemost 100: 498-504. 
Aster RH. Improving specificity in HIT testing. Blood 2010; 116: 1632-1633. 
Chang JJ, Parikh CR. (2006) When heparin causes thrombosis: significance, recognition, and 
management of heparin-induced thrombocytopenia in dialysis patients. Semin Dial 
19: 297-304. 
www.intechopen.com
 
Renal Failure – The Facts 
 
214 
Carrier M, Rodger MA, Fergusson D, Doucette S, Kovacs MJ, Moore J, Kelton JG, Knoll GA. 
(2008) Increased mortality in hemodialysis patients having specific antibodies to 
the platelet factor 4-heparin complex. Kidney Int 73: 213-219. 
Davenport A. Sudden collapse during haemodialysis due to immune-mediated heparin-
induced thrombocytopenia. (2006) Nephrol Dial Transplant  21: 1721-1724. 
Davenport A. (2009) Antibodies to heparin–platelet factor 4 complex: pathogenesis, 
epidemiology, and management of heparin-induced thrombocytopenia in 
hemodialysis. Am J Kidney Dis, 54; 361-374 
EI-Shahawy, M, Noureddin M, Abdullah H, Mack WJ, Calverley DC. (2007) Platelet 
FcgammaRIIA receptor surface expression is increased in patients with ESRD and 
is associated with atherosclerotic cardiovascular events. Am J Kidney Dis 49: 127-
134. 
Gozdzikiewicz J, Borawski J, Mysliwiec M. (2007) Treatment of heparin-induced 
thrombocytopenia type II in hemodialysis patients: the search for a holy grail 
continues. Clin Appl Thromb/Hemost 13:110-111. 
Holmes CE, Huang JC, Cartelli C, Howard A, Rimmer J, Cushman M. (2009) The clinical 
diagnosis of heparin-induced thrombocytopenia in patients receving continuous 
renal replacement therapy. J Thromb Thromboly 27:406-412. 
Hartman V, Malbrain M, Daelemans R, Meersman P, Zachee P. (2006) Psudo-pulmonary 
embolism as a sign of acute heparin-induced thrombocytopenia in hemodialysis 
patients: safety of resuming heparin after disappearnance of HIT antibodies. 
Nephron Clin Pract 104:c143-148. 
Hursting M, Murray P. (2008) Argatroban anticoagulation in renal dysfunction: a literature 
analysis. Nephron Clin Pract  109:c80-c94. 
Hutchison CA, Dasgupta I. (2005) National survey of heparin-induced thrombocytopenia in 
the haemodialysis population of the UK population. Nephrol Dial Transplant 20: 
444-446. 
Lasocki S, Piednoir P, Ajzenberg N, Geffroy A, Benbara A, Montravers P. (2008) Anti-
PF4/heparin antibodies associated with repeated hemofiltration-filter clotting: a 
retrospective study. Crit Care 12(3) R84 Epub. 
Matsuo T, Chikahira Y, Yamada Y, Nakao K, Uesima S, Matsuo O. (1988) Effect of synthetic 
thrombin inhibitor (MD805) as an alternative drug on heparin induced 
thrombocytopenia during hemodialysis. Thromb Res 52; 165-171.  
Matsuo T, Yamada T, Yamanashi T, Ryo R. (1990) Anticoagulant therapy with MD805 of a 
hemodialysis patient with heparin-induced thrombocytopenia. Thromb Res 58; 
663-666. 
Matsuo T, Matsuo M, Ouga-Maruyama S. Can nafamostat mesilate be used for temporary 
management of hemodialysis in a patient with heparin-induced thrombocytopenia 
(HIT)? (2001) Thromb Haemost 86; 1115-1116. 
Matsuo T, Matsuo M, Wanaka, K, Sakai R. (2003) Heparin re-exposure after heparin-induced 
thrombocytopenia in a chronic hemodialysis patient. Clin Lab Haematol 25: 333-
334. 
Matsuo T, Kobayashi H, Matsuo M, Wanaka K, Nakamoto H, Matsusima H, Sakai R. (2006) 
Frequency of anti-heparin-PF4 complex antibodies (HIT antibodies) in uremic 
patients on chronic intermittent hemodialysis. Pathphysiol Haemost Thromb; 
35:445-450. 
www.intechopen.com
 
Management of Heparin-Induced Thrombocytopenia in Uremic Patients with Hemodialysis 
 
215 
Matsuo T, Kusano H, Wanaka K, Ishihara M, Oyama A. (2007) Heparin-induced 
thrombocytopenia in a uremic patient requiring hemodialysis: an alternative 
treatment and reexposure to heparin. Clin Appl Thromb Hemost. 13:182-7 
Matsuo T, Wanaka K. Hemodialysis and argatroban. (2008a) Semin Thromb Hemost 34 
(Suppl 1); 56-61. 
Matsuo T, Wanaka K. Management of uremic patients with heparin-induced 
thrombocytopenia requiring hemodialysis. (2008b) Clin Appl Thromb Hemost 14; 
459-464. 
Mureebe L, Coats RD, Silliman WR, Shouster TA, Nichols WK, Silver D. (2004) Heparin-
associated antiplatelet antibodies increase morbidity and mortality in hemodialysis 
patients. Surgery 136:848-853. 
Nakamoto H, Shimada Y, Kanno T, Wanaka K, Matsuo T, Suzuki H.(2005) Role of platelet 
factor 4-heparin complex antibody (HIT antibody) in the pathogenesis of 
thrombotic episodes in patients on hemodialysis. Hemodial Int  9(suppl 1):s2-5. 
O’Shea SI, Sands JJ, Nudo SA, Ortel TL. (2002) Frequency of anti-heparin-platelet factor 4 
antibodies in hemodialysis patients and correlation with recurrent vascular 
thrombosis. Am J Hematol 69:72-73. 
Oliveria GBF, Crespo EM, Becker RC, Honeycutt EF, Abrams CS, Anstrom KJ, Berger PB, 
Davidson-Ray LD, Eisenstein EL, Kleiman NS, Moliterno DJ, Moll S, Rice L, 
Rodgers JO, Steinhubl SR, Tapson VF, Ohman EM, Granger CB. (2008) Incidence 
and prognostic significance of thrombocytopenia in patients treated with 
prolonged heparin therapy. Arch Intern Med 168:94-102. 
Pouplard C, Amiral J, Borg JY, Laporte-Simitsidis S, Delahousse B, Gruel Y. (1999) Decision 
analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and 
heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of 
heparin-induced thrombocytopenia. Am J Clin Pathol  111:700-706. 
Roncon-Albuquerque R, Beco A, Ferreira AL, Gomes-Carvalho C, Costa A, Frazao J, Pestana 
M, von Hafe P. (2010) Therapeutic implications of heparin-induced 
thrombocytopenia complicating acute hemodialysis. Clin Nephrol 73: 326-330. 
Selleng K, Schutt A, Selleng S, Warkentin TE, Greinacher A. Studies of the anti-PF4/heparin 
immune response: adapting the enzyme-linked immunosorbent spot assay for 
detection of memory B cells antigens. (2010) Transfusion 50; 32-39. 
Shaheed G, Malkovska V, Mendoza J, Patel M, Rees J, Wesley R, Merryman P, Horne M. 
(2007)  PF4 ENHANCD assay for the diagnosis of heparin-induced 
thrombocytopenia in complex medical and surgical patients. Crit Care Med 
35:1784-1785. 
Sheriden D, Carter C, Kelton JG. (1986) A diagnostic test for heparin-induced 
thrombocytopenia. Blood 67: 27-30. 
Sonawane S, Kasbekar N, Berns JS. (2006) The safety of heparins in end-stage renal disease. 
Semin Dial 19:305-310. 
Syed S, Reilly RF. (2009) Heparin-induced thrombocytopenia: a renal perspective. Nat Rev 
Nephrol 5: 501-511. 
Tejedor Alonso, MA, Revuelta Lopez K, Garcia Bueno MJ, Casas L,Osada ML, Ingelmo 
Rosado A, Gruss Vergara E, Vila Albelda C, Moro Moro M. (2005) 
Thrombocytopenia and anaphylaxis secondary to heparin in a hemodialysis 
patient. Clin Nepherol  63: 236-240 
www.intechopen.com
 
Renal Failure – The Facts 
 
216 
Warkentin TE, Sheppaed JI, Moore JC, Sigouin CS, Kelton JG. (2008) Quantitative 
interpretation of optical density measurements using PF4-dependent enzyme-
immunoassays. J Throm Haemost 6: 1304-1312. 
Warkentin TE, Greinacher A. (2009) Heparin-induced anaphylactic and anaphylactoid 
reactions: two distinct but overlapping syndromes. Expert Opin Drug Saf 8; 129-
144.  
Wanaka K, Matsuo T, Matsuo M, Kaneko C, Miyasita K, Asada R, Matsusima H, Nakajima 
Y. (2010) Re-exposure to heparin in uremic patients requiring hemodialysis with 
heparin-induced thrombocytopenia. J Thromb Haemost 8; 616-618.  
Weiss BM, Shumway NM, Howard RS, Ketchum LK, Reid TJ. (2008) Optical density values 
correlate with the clinical probability of heparin-induced thrombocytopenia. J 
Thromb Thrombolysis 26; 26: 243-247. 
Yamamoto S, Koide M, Matsuo M, Suzuki S, Ohtaka M, Saika S, Matsuo T. (1996) Heparin-
induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis 28:82-85. 
www.intechopen.com
Renal Failure - The Facts
Edited by Dr. Momir Polenakovic
ISBN 978-953-51-0630-2
Hard cover, 270 pages
Publisher InTech
Published online 23, May, 2012
Published in print edition May, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The book "Renal Failure - The Facts" consists of some facts about diagnosis, etiopathogenis and treatment of
acute and chronic renal failure. Acute, as well as chronic renal failure is great medical problems and their
treatment is a burden for the budget of each government. The purpose of the chapters is to present some
important issues of diagnosis and causes of AKI, as well as caused by snakes and arthropods, after cardiac
surgery, as well as some therapeutic achievements in AKI. Well presented are the psychological condition in
patients on haemodialysis, as well as the treatment of diabetic uremics. The book is aimed at clinicians with a
special interest in nephrology, but it should also prove to be a valuable resource for any generalists who
encounter a nephrological problems in their day-to-day practice.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Takefumi Matsuo (2012). Management of Heparin-Induced Thrombocytopenia in Uremic Patients with
Hemodialysis, Renal Failure - The Facts, Dr. Momir Polenakovic (Ed.), ISBN: 978-953-51-0630-2, InTech,
Available from: http://www.intechopen.com/books/renal-failure-the-facts/management-of-heparin-induced-
thrombocytopenia-hit-in-uremic-patients-with-hemodialysis-hd
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
